A leadership change has led to significant disruption at C3.ai.
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFA15 Sept 2025, 15:45 UTC
AI-generated source summary
The analysis discusses C3.ai (AI) and its change in leadership, including Tom Siebel stepping down due to health issues. The recent quarterly performance showed a 20% revenue decline year-over-year. However, despite the negative news and revenue decline the analyst is upgrading the stock to a buy, but indicates the current CEO will advise the new incoming CEO. The company has $700 million in cash and equivalents with zero debt, positioning it favorably. Customer satisfaction is measured by the net promoter score. I calculate the fair value of the stock at $32 and the current market price is only $16 the analyst concludes that it's an upgrade to a buy.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Signals in this source
More Prediction Case Files from Parkev Tatevosian, CFA
Coca-Cola Stock: Buy, Hold, or Sell? | KO Stock Analysis
SoFi Stock Analysis: Buy the Dip?
Should You Buy Micron Stock Instead of Nvidia Stock? | MU Stock vs. NVDA Stock
Should You Buy the Dip in Meta Stock? | META Stock Analysis and Live Earnings Review
Should Passive Income Investors Buy Colgate Palmolive Stock?
Procter & Gamble Stock: Buy, Hold, or Sell? | PG Stock Analysis
Parkev Tatevosian, CFA
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.